Bevacizumab biosimilar - Boehringer Ingelheim

Drug Profile

Bevacizumab biosimilar - Boehringer Ingelheim

Alternative Names: BI 695502

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase I Cancer

Most Recent Events

  • 01 Aug 2017 Phase-I development is ongoing for Cancer (In volunteers) in New Zealand
  • 01 Aug 2017 Boehringer Ingelheim terminates the phase IINVICTAN-1 trial in Healthy volunteers in New Zealand (IV) (NCT01608087)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in New Zealand (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top